| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |